In the latest trading session, 1.16 million Nuvation Bio Inc (NYSE:NUVB) shares changed hands as the company’s beta touched 1.38. With the company’s most recent per share price at $1.75 changing hands around $0.09 or 5.12% at last look, the market valuation stands at $591.00M. NUVB’s current price is a discount, trading about -126.86% off its 52-week high of $3.97. The share price had its 52-week low at $1.57, which suggests the last value was 10.29% up since then. When we look at Nuvation Bio Inc’s average trading volume, we note the 10-day average is 2.67 million shares, with the 3-month average coming to 2.67 million.
Analysts gave the Nuvation Bio Inc (NUVB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NUVB as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Nuvation Bio Inc’s EPS for the current quarter is expected to be -0.12.
Nuvation Bio Inc (NYSE:NUVB) trade information
Instantly NUVB is in green as seen in intraday trades today. With action -0.85%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -34.40%, with the 5-day performance at -0.85% in the red. However, in the 30-day time frame, Nuvation Bio Inc (NYSE:NUVB) is -13.61% down. Looking at the short shares, we see there were 28.39 million shares sold at short interest cover period of 9.84 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 70.83% from its recent market value. According to analyst projections, NUVB’s forecast low is 5 with 10 as the target high. To hit the forecast high, the stock’s price needs a -471.43% plunge from its current level, while the stock would need to soar -185.71% for it to hit the projected low.
Nuvation Bio Inc (NUVB) estimates and forecasts
Year-over-year growth is forecast to reach 72.24% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 416.67k. 6 analysts are of the opinion that Nuvation Bio Inc’s revenue for the current quarter will be 416.67k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at -70.96%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -49.14%. The 2025 estimates are for Nuvation Bio Inc earnings to increase by 73.12%, but the outlook for the next 5-year period is at 37.20% per year.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 26.68% of Nuvation Bio Inc shares while 58.93% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.38%. There are 58.93% institutions holding the Nuvation Bio Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 11.7767% of the shares, roughly 28.82 million NUVB shares worth $84.16 million.
ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 7.8491% or 19.21 million shares worth $56.09 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 15.47 shares estimated at $25.83 million under it, the former controlled 4.58% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.65% of the shares, roughly 8.96 shares worth around $14.96 million.
